See more : Cyxtera Technologies, Inc. (CYXT) Income Statement Analysis – Financial Results
Complete financial analysis of Carisma Therapeutics, Inc. (CARM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carisma Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Longyuan Power Group Corporation Limited (CLPXY) Income Statement Analysis – Financial Results
- Sato Sangyo Co., Ltd. (3450.T) Income Statement Analysis – Financial Results
- Decmil Group Limited (DCG.AX) Income Statement Analysis – Financial Results
- Okinawa Cellular Telephone Company (OKCTF) Income Statement Analysis – Financial Results
- Jindalee Resources Limited (JRL.AX) Income Statement Analysis – Financial Results
Carisma Therapeutics, Inc. (CARM)
About Carisma Therapeutics, Inc.
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.92M | 9.83M | 26.54M | 11.24M | 0.00 | 0.00 | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Cost of Revenue | 74.13M | 6.09M | 85.00K | 0.00 | 219.00K | 208.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -59.21M | 3.74M | 26.46M | 11.24M | -219.00K | -208.00K | 425.00K | 29.98M | 990.00K | 2.24M | 1.33M | 0.00 | 0.00 |
| Gross Profit Ratio | -396.85% | 38.07% | 99.68% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 74.13M | 56.62M | 34.39M | 23.29M | 24.44M | 13.87M | 12.23M | 12.20M | 25.97M | 26.70M | 13.79M | 15.26M | 9.41M |
| General & Administrative | 29.53M | 9.38M | 6.41M | 5.09M | 12.21M | 11.62M | 8.07M | 14.74M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Selling & Marketing | 0.00 | 30.41M | 0.00 | 0.00 | 0.00 | 0.00 | -170.00K | -3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.53M | 3.29M | 6.41M | 5.09M | 12.21M | 11.62M | 7.90M | 11.44M | 9.85M | 8.47M | 4.02M | 4.21M | 3.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.65M | 59.91M | 40.79M | 28.38M | 36.65M | 25.49M | 20.13M | 23.64M | 35.82M | 35.17M | 17.81M | 19.48M | 12.68M |
| Cost & Expenses | 103.65M | 66.00M | 40.79M | 28.38M | 36.87M | 25.70M | 20.41M | 23.82M | 36.19M | 35.17M | 17.81M | 19.48M | 12.68M |
| Interest Income | 1.94M | 1.85M | 10.00K | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 247.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Depreciation & Amortization | 2.84M | 6.09M | 85.00K | 122.00K | 219.00K | 208.00K | 285.00K | 178.00K | 366.00K | 410.00K | 438.00K | 448.00K | 364.00K |
| EBITDA | -85.89M | -51.99M | -40.11M | -27.93M | -107.28M | -33.49M | -28.74M | 2.32M | -31.69M | -33.37M | -17.18M | -19.04M | -12.31M |
| EBITDA Ratio | -575.74% | -509.17% | -151.12% | -248.58% | 0.00% | 0.00% | -4,635.29% | 21.16% | -3,518.18% | -1,487.74% | -1,213.42% | 0.00% | 0.00% |
| Operating Income | -88.73M | -56.16M | -40.79M | -28.38M | -36.87M | -25.70M | -19.99M | 6.17M | -35.20M | -33.78M | -16.63M | -19.49M | -12.68M |
| Operating Income Ratio | -594.75% | -571.10% | -153.68% | -252.56% | 0.00% | 0.00% | -4,702.35% | 20.57% | -3,555.15% | -1,506.02% | -1,246.25% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.85M | -5.06M | 10.00K | 29.00K | -70.63M | -7.99M | -9.04M | -4.27M | 1.74M | -1.23M | -1.40M | -168.00K | -151.00K |
| Income Before Tax | -86.88M | -61.23M | -40.78M | -28.35M | -107.50M | -33.69M | -29.03M | 1.90M | -33.45M | -34.16M | -18.03M | -19.66M | -12.83M |
| Income Before Tax Ratio | -582.34% | -622.60% | -153.65% | -252.31% | 0.00% | 0.00% | -6,830.35% | 6.32% | -3,378.99% | -1,522.78% | -1,351.20% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.88M | -10.00K | -29.00K | 0.00 | 46.86K | 0.00 | 5.00K | 1.40M | 376.00K | 1.40M | 168.00K | 151.00K |
| Net Income | -86.88M | -61.23M | -40.77M | -28.32M | -107.50M | -33.69M | -29.03M | 1.89M | -33.45M | -34.53M | -19.43M | -19.83M | -12.98M |
| Net Income Ratio | -582.34% | -622.60% | -153.61% | -252.05% | 0.00% | 0.00% | -6,830.35% | 6.31% | -3,378.99% | -1,539.55% | -1,456.15% | 0.00% | 0.00% |
| EPS | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.79 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| EPS Diluted | -2.59 | -575.42 | -4.47 | -4.79 | -23.64 | -10.91 | -22.24 | 1.74 | -35.23 | -47.16 | -45.50 | -55.70 | -30.39 |
| Weighted Avg Shares Out | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.05M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
| Weighted Avg Shares Out (Dil) | 33.52M | 106.40K | 9.12M | 5.91M | 4.55M | 3.09M | 1.31M | 1.09M | 949.65K | 732.20K | 426.95K | 355.90K | 426.95K |
Best Momentum Stocks to Buy for August 15th
BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
Why Shares Of Sesen Bio Are Down 28% Today
Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to voluntarily pause further development in the US of its lead asset, Vicineum. What Happened?
Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC). The decision was based on a reassessment of the incremental development.
Which Industries Are Penny Stocks Investors Watching Right Now
Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
VERU's Shares Jump on Successful COVID-19 Study Results
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?
Top Penny Stocks To Buy For Under $1? 3 To Watch This Week
Stocks Under $1 To Watch This Week. The post Top Penny Stocks To Buy For Under $1?
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Source: https://incomestatements.info
Category: Stock Reports